BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The November 2013 issue of BioPharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with MAB Discovery GmbH
Europe's upwelling Steven Edelson and Kai-Jye Lou doi:10.1038/scibx.2014.188 SciBX's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's PPP activity in 2013 surpassed that of the U.S. in dramatic fashion. Full Text | PDF
BAND-aid for PD and AD Michael J. Haas doi:10.1038/scibx.2014.189 Evidence for overlaps between PD and AD have led three foundations to launch the BAND grant program to fund cross-disease research. The studies will use outputs from both the Parkinson's Progression Markers Initiative and the Alzheimer's Disease Neuroimaging Initiative. Full Text | PDF
Preserving the oocyte reserve Tracey Baas doi:10.1038/scibx.2014.190 A Cornell team has preserved fertility in mice by knocking out checkpoint kinase 2. The target offers companies a new opportunity for preventing chemotherapy- and radiotherapy-induced premature menopause and infertility. Full Text | PDF
Degradation from within Lev Osherovich doi:10.1038/scibx.2014.191 A Cornell group has proof of concept for proteasomal degradation of intracellular proteins using designer binding proteins to deliver ubiquitin to their targets. The challenge for Ubiquizyme, a newco formed around this concept, is to deliver its molecules in a therapeutic setting. Full Text | PDF
Invariant NK T (iNKT) cells doi:10.1038/scibx.2014.192 In vitro and mouse studies suggest Bacteroides fragilis–derived glycosylceramide sphingolipids (GL-Cers) could help treat IBD by inhibiting activation of iNKT cells. Full Text | PDF
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily a member 4 (SMARCA4; BRG1) doi:10.1038/scibx.2014.193 Studies in cell culture and mice suggest inhibiting BRG1 could help treat AML. Full Text | PDF
TANK-binding kinase 1 (TBK1); estrogen receptor doi:10.1038/scibx.2014.194 In vitro, mouse and patient sample studies suggest inhibiting TBK1 could help treat tamoxifen-resistant breast cancer and that measuring TBK1 expression could help predict response to tamoxifen. Full Text | PDF
Procaspase-3 doi:10.1038/scibx.2014.195 In vitro and mouse studies suggest combining compounds that activate procaspase-3 by different mechanisms could help treat cancer. Full Text | PDF
Stage-specific embryonic antigen-4 (SSEA-4) doi:10.1038/scibx.2014.196 Human sample, in vitro and mouse studies suggest an anti-SSEA-4 mAb could be used to treat glioblastoma. Full Text | PDF
Spleen tyrosine kinase (SYK) doi:10.1038/scibx.2014.197 Primary tumor studies suggest measuring levels of two SYK isoforms could help predict treatment outcomes in patients with HCC. Full Text | PDF
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily a member 4 (SMARCA4; BRG1) doi:10.1038/scibx.2014.198 Cell culture studies suggest inhibiting BRG1 could help treat MYC associated factor X (MAX) mutant small cell lung cancer (SCLC). Full Text | PDF
Checkpoint kinase 2 (Chk2; CHEK2) doi:10.1038/scibx.2014.199 Mouse studies suggest inhibiting CHK2 could prevent premature ovarian failure after radiotherapy or chemotherapy. Full Text | PDF
α-l-iduronidase (IDUA) doi:10.1038/scibx.2014.200 In vitro and mouse studies suggest megakaryocyte-targeted gene therapy could help treat mucopolysaccharidosis I (MPS I; Hurler syndrome). Full Text | PDF
Hepcidin doi:10.1038/scibx.2014.201 In vitro and mouse studies identified modified forms of heparin that could help treat chronic anemia. Full Text | PDF
IgA doi:10.1038/scibx.2014.202 Mouse studies suggest secretory IgA could help prevent bacterial infections in formula-fed neonates. Full Text | PDF
Triggering receptor expressed on myeloid cells 1 (TREM1) doi:10.1038/scibx.2014.203 Mouse studies suggest inhibiting the innate immune receptor TREM1 could help reduce inflammation caused by infection. Full Text | PDF
Mycobacterium tuberculosis transmembrane serine/threonine-protein kinase B (pknB) doi:10.1038/scibx.2014.204 Cell culture studies suggest inhibiting M. tuberculosis pknB could be useful for treating tuberculosis. Full Text | PDF
Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32) doi:10.1038/scibx.2014.205 In vitro and mouse studies identified NRF2 pathway activators that could help treat PD. Full Text | PDF
Diagnosing and monitoring treatment responses in patients with Niemann-Pick disease type C1 (NPC1) using fluorescence-based volumetric measurement of lysosomes doi:10.1038/scibx.2014.206 A fluorescence-based assay in B cells could help monitor treatment responses and diagnose patients with NPC1. Full Text | PDF
Screening antimetastatic compounds using microfluidic-based tracking of cell migration doi:10.1038/scibx.2014.207 A microfluidic device that monitors cell migration could be used to screen antimetastatic compounds. Full Text | PDF
Bone marrow niche–sensitizing chemotherapy to enhance antibody-based acute lymphoblastic leukemia (ALL) elimination doi:10.1038/scibx.2014.208 Mouse and human sample studies suggest targeting tumor type–specific factors that suppress antitumor immunity could help eliminate residual ALL. Full Text | PDF
Improved brain delivery of anti–transferrin receptor (TFRC; TFR)-containing antibodies by reducing TFRC affinity doi:10.1038/scibx.2014.209 Mouse studies suggest lowering anti-TFRC antibody affinity could increase brain uptake of blood brain barrier (BBB)-penetrant, bispecific antibodies. Full Text | PDF
Inducing multipotent progenitor cells from keratinocytes by depleting the tumor protein p63 (TP63; p63) ΔNp63 isoform or DGCR8 microprocessor complex subunit (DGCR8) doi:10.1038/scibx.2014.210 In vitro studies suggest depleting ΔNp63 or DGCR8 in keratinocytes could induce their conversion into multipotent stem cells. Full Text | PDF
Intracellularly expressed antibodies linked to the E3 ubiquitin ligase domain of STIP1 homology and U-box containing protein 1 (STUB1; CHIP) to enable targeted protein degradation doi:10.1038/scibx.2014.211 In vitro and cell culture studies suggest intracellular expression of antibodies linked to the E3 ubiquitin ligase domain of CHIP could promote ubiquitin-mediated degradation of target proteins. Full Text | PDF
Retinal progenitor cell therapy for retinal degeneration doi:10.1038/scibx.2014.212 Rat studies suggest transplantation of retinal progenitor cells could help treat or prevent retinal degeneration. Full Text | PDF
Viral insertion of inducible aptazymes to improve the safety of oncolytic viral therapy doi:10.1038/scibx.2014.213 In vitro studies suggest inducible aptazymes that regulate viral gene expression could improve the safety of oncolytic viruses. Full Text | PDF
A cytosine methylation signature that predicts overall survival in acute myelogenous leukemia (AML) doi:10.1038/scibx.2014.214 Studies of human samples suggest a cytosine methylation signature can predict overall survival of patients with AML. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment